JP2020501531A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020501531A5 JP2020501531A5 JP2019527232A JP2019527232A JP2020501531A5 JP 2020501531 A5 JP2020501531 A5 JP 2020501531A5 JP 2019527232 A JP2019527232 A JP 2019527232A JP 2019527232 A JP2019527232 A JP 2019527232A JP 2020501531 A5 JP2020501531 A5 JP 2020501531A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 34
- 239000000427 antigen Substances 0.000 claims 31
- 102000036639 antigens Human genes 0.000 claims 31
- 108091007433 antigens Proteins 0.000 claims 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims 20
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 13
- 230000035772 mutation Effects 0.000 claims 13
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 108091035707 Consensus sequence Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 231100000433 cytotoxic Toxicity 0.000 claims 3
- 230000001472 cytotoxic effect Effects 0.000 claims 3
- 102000050327 human TNFRSF9 Human genes 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 2
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 2
- 102000009109 Fc receptors Human genes 0.000 claims 2
- 108010087819 Fc receptors Proteins 0.000 claims 2
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 2
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 238000002648 combination therapy Methods 0.000 claims 2
- 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 229940116741 CD137 agonist Drugs 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102000018297 Immunoglobulin subtype Human genes 0.000 claims 1
- 108050007411 Immunoglobulin subtype Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 201000004458 Myoma Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 230000009260 cross reactivity Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000007246 mechanism Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1619648.7 | 2016-11-21 | ||
| GBGB1619648.7A GB201619648D0 (en) | 2016-11-21 | 2016-11-21 | Novel antibodies and uses thereof |
| PCT/EP2017/079930 WO2018091740A2 (en) | 2016-11-21 | 2017-11-21 | Novel antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020501531A JP2020501531A (ja) | 2020-01-23 |
| JP2020501531A5 true JP2020501531A5 (OSRAM) | 2020-12-17 |
| JP7068303B2 JP7068303B2 (ja) | 2022-05-16 |
Family
ID=57993708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019527232A Active JP7068303B2 (ja) | 2016-11-21 | 2017-11-21 | 新規抗ｃｄ１３７抗体およびその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11535678B2 (OSRAM) |
| EP (1) | EP3541844A2 (OSRAM) |
| JP (1) | JP7068303B2 (OSRAM) |
| KR (1) | KR102679632B1 (OSRAM) |
| CN (1) | CN109963873B (OSRAM) |
| AU (1) | AU2017360094B2 (OSRAM) |
| BR (1) | BR112019010265A2 (OSRAM) |
| CA (1) | CA3044339A1 (OSRAM) |
| GB (1) | GB201619648D0 (OSRAM) |
| IL (1) | IL266738B2 (OSRAM) |
| MX (1) | MX2019005911A (OSRAM) |
| NZ (1) | NZ754051A (OSRAM) |
| RU (1) | RU2019116624A (OSRAM) |
| WO (1) | WO2018091740A2 (OSRAM) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11214618B2 (en) | 2016-06-20 | 2022-01-04 | F-Star Therapeutics Limited | LAG-3 binding members |
| AU2018206015B2 (en) * | 2017-01-06 | 2019-05-30 | Eutilex Co., Ltd. | Anti-human 4-1 BB antibodies and use thereof |
| BR112019017241A2 (pt) | 2017-04-13 | 2020-04-14 | Agenus Inc | anticorpos anti-cd137 e métodos de uso dos mesmos |
| US11512134B2 (en) | 2017-08-01 | 2022-11-29 | Eli Lilly And Company | Anti-CD137 antibodies |
| BR112020001441A2 (pt) | 2017-08-01 | 2020-08-04 | Eli Lilly And Company | anticorpos anti-cd137 |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| US12037406B2 (en) | 2018-03-23 | 2024-07-16 | Eli Lilly And Company | Anti-CD137 antibodies for combination with anti-PD-L1 antibodies |
| GB201811408D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811404D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| CN112423845B (zh) | 2018-07-12 | 2024-07-30 | F-星治疗有限公司 | 结合pd-l1和cd137的抗体分子 |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| CA3106048A1 (en) | 2018-07-12 | 2020-01-16 | F-Star Beta Limited | Antibody molecules that bind cd137 and ox40 |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| AU2019312200B2 (en) | 2018-07-23 | 2024-11-14 | Heidelberg Pharma Research Gmbh | Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy |
| EP3835321A4 (en) * | 2018-08-10 | 2022-11-02 | Chugai Seiyaku Kabushiki Kaisha | ANTI-CD137 ANTIGEN-BINDING MOLECULE AND USE THEREOF |
| BR112021004698A2 (pt) * | 2018-09-12 | 2021-06-01 | Eucure (Beijing) Biopharma Co., Ltd | anticorpos anti-tnfrsf9 e usos dos mesmos |
| CN113382752B (zh) * | 2019-01-02 | 2025-03-04 | Qlsf生物治疗药物公司 | Cd137激动剂抗体及其用途 |
| WO2020216947A1 (en) | 2019-04-24 | 2020-10-29 | Heidelberg Pharma Research Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| CA3144617A1 (en) * | 2019-06-26 | 2020-12-30 | Ap Biosciences, Inc. | Antibodies for t-cell activation |
| JP7432716B2 (ja) * | 2019-11-13 | 2024-02-16 | 合肥瀚科邁博生物技術有限公司 | ヒト４－１ｂｂに結合可能な分子及びその応用 |
| JP2023509516A (ja) | 2020-01-07 | 2023-03-08 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | がん治療のための改良型ヒトメチルチオアデノシン／アデノシン枯渇酵素変種 |
| WO2021170067A1 (zh) * | 2020-02-28 | 2021-09-02 | 上海复宏汉霖生物技术股份有限公司 | 抗cd137构建体及其用途 |
| WO2021236658A1 (en) | 2020-05-19 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
| CN113842456B (zh) * | 2020-06-28 | 2022-07-26 | 上海齐鲁制药研究中心有限公司 | 一种抗人4-1bb的单克隆抗体制剂及其用途 |
| US20230242658A1 (en) * | 2020-06-30 | 2023-08-03 | Nona Biosciences (Suzhou) Co., Ltd. | 4-1bb-binding protein and use thereof |
| EP4276111A4 (en) * | 2021-01-08 | 2025-04-30 | Beijing Hanmi Pharmaceutical Co., Ltd. | Antibody specifically binding to 4-1bb and antigen-binding fragment of antibody |
| EP4355780A1 (en) | 2021-06-18 | 2024-04-24 | Alligator Bioscience AB | Novel combination therapies and uses thereof |
| GB202210957D0 (en) | 2022-07-27 | 2022-09-07 | Alligator Bioscience Ab | Novel dosages |
| GB202210965D0 (en) | 2022-07-27 | 2022-09-07 | Alligator Bioscience Ab | Novel dosages |
| EP4572772A1 (en) | 2022-08-17 | 2025-06-25 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024061364A1 (zh) * | 2022-09-22 | 2024-03-28 | 成都盛世君联生物技术有限公司 | 一种抗4-1bb纳米抗体及其制备和应用 |
| CN116162162B (zh) * | 2022-12-19 | 2025-05-27 | 首都医科大学附属北京胸科医院 | 一种大鼠抗小鼠cd137抗体或其功能性片段、工具抗体及其应用 |
| CN116041517B (zh) * | 2022-12-19 | 2025-02-25 | 首都医科大学附属北京胸科医院 | 一种抗人cd137抗体及其应用 |
| CN116271009A (zh) * | 2023-01-13 | 2023-06-23 | 深圳市乐土生物医药有限公司 | 含有CpG佐剂和4-1BB抗体的药物组合物及其用途 |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| AR046094A1 (es) * | 2003-10-10 | 2005-11-23 | Bristol Myers Squibb Co | Anticuerpos completamente humanos contra 4-1bb humano |
| JP5496669B2 (ja) | 2006-09-01 | 2014-05-21 | ジェンティセル | リンパ除去化合物、および抗原配列を含みかつプロフェッショナル抗原提示細胞をターゲットとする分子を含んでなる、特異的ｃｔｌ応答を誘発する組成物 |
| WO2016029073A2 (en) * | 2014-08-22 | 2016-02-25 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
| EP3258959A4 (en) * | 2015-02-22 | 2018-10-17 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind cd137 |
| RU2017142008A (ru) | 2015-05-21 | 2019-06-24 | Эллигейтор Биосайенс Аб | Новые полипептиды |
-
2016
- 2016-11-21 GB GBGB1619648.7A patent/GB201619648D0/en not_active Ceased
-
2017
- 2017-11-21 MX MX2019005911A patent/MX2019005911A/es unknown
- 2017-11-21 CN CN201780071444.6A patent/CN109963873B/zh active Active
- 2017-11-21 EP EP17811475.7A patent/EP3541844A2/en active Pending
- 2017-11-21 AU AU2017360094A patent/AU2017360094B2/en active Active
- 2017-11-21 NZ NZ754051A patent/NZ754051A/en unknown
- 2017-11-21 RU RU2019116624A patent/RU2019116624A/ru unknown
- 2017-11-21 CA CA3044339A patent/CA3044339A1/en active Pending
- 2017-11-21 IL IL266738A patent/IL266738B2/en unknown
- 2017-11-21 WO PCT/EP2017/079930 patent/WO2018091740A2/en not_active Ceased
- 2017-11-21 US US16/461,544 patent/US11535678B2/en active Active
- 2017-11-21 KR KR1020197015905A patent/KR102679632B1/ko active Active
- 2017-11-21 JP JP2019527232A patent/JP7068303B2/ja active Active
- 2017-11-21 BR BR112019010265A patent/BR112019010265A2/pt unknown
-
2019
- 2019-07-17 US US16/514,374 patent/US10689454B2/en active Active
-
2022
- 2022-11-10 US US18/054,373 patent/US20230295325A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020501531A5 (OSRAM) | ||
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| RU2019116624A (ru) | Новые анти_cd137 антитела и их применение | |
| JP5723279B2 (ja) | 抗ｃｘｃｒ４抗体および癌治療のためのそれらの使用 | |
| JP2021531764A5 (OSRAM) | ||
| JP2017519759A5 (OSRAM) | ||
| JP2009541492A5 (OSRAM) | ||
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| CN117946278A (zh) | 多特异性抗体及其制备和使用方法 | |
| CN116948035A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2019512207A5 (OSRAM) | ||
| CN112292399A (zh) | 抗cd27抗体及其用途 | |
| CA3146986A1 (en) | Anti-tigit antibodies and application thereof | |
| JP2020502233A5 (OSRAM) | ||
| JP2024517760A (ja) | 抗５ｔ４抗体及びその使用 | |
| KR20230028386A (ko) | 인간 질환의 치료를 위한 cd38 항체 | |
| AU2019306113B2 (en) | Anti-human PD-L1 antibodies and their uses | |
| JPWO2021068841A5 (OSRAM) | ||
| JPWO2020218951A5 (OSRAM) | ||
| WO2024113099A1 (en) | Protease cleavable recombinant bispecific antibodies and compositions and uses thereof | |
| RU2024126025A (ru) | Антитела против msln и способы их применения | |
| HK40088417A (zh) | 多特异性抗体及其制备和使用方法 | |
| HK40088418A (zh) | 多特异性抗体及其制备和使用方法 | |
| RU2024119982A (ru) | Антитела к ox40, полиспецифические антитела и способы их применения | |
| CN115246884A (zh) | 抗pd-l1单域抗体及其用途 |